合并显著共病的受者评估——心血管疾病患者
综述讨论肝移植候选者心血管评估的最新证据,聚焦缺血性心脏病、心房颤动及其他心律失常、瓣膜性心脏病和心肌病。标准移植前评估包括心电图、静息经胸超声心动图和心肺功能评估,有心血管危险因素者可进一步行冠状动脉计算机断层扫描血管成像,评估需多学科参与。
要点
- 肝移植候选者标准移植前评估包括心电图、静息经胸超声心动图和心肺功能评估。
- 有心血管危险因素的患者可进一步行冠状动脉计算机断层扫描血管成像。
- 心血管疾病评估需麻醉科、心内科、肝病科和移植外科多学科参与。
核心结论
- 心血管疾病是肝移植后发病和死亡的主要原因,移植前全面心血管评估至关重要。
研究设计与样本
- 综述,讨论肝移植候选者心血管评估的最新证据。
主要发现
- 肥胖和2型糖尿病患病率增加及非酒精性脂肪性肝病评估人数增多,使更多肝移植候选者呈现较高心血管疾病风险。
- 综述聚焦缺血性心脏病、心房颤动及其他心律失常、瓣膜性心脏病和心肌病。
关键数值与推荐
- 肝移植候选者标准移植前评估包括心电图、静息经胸超声心动图和心肺功能评估。
- 根据基线评估结果进一步诊断,有心血管危险因素的患者可行冠状动脉计算机断层扫描血管成像。
临床怎么用
- 肝移植候选者心血管疾病评估需麻醉科、心内科、肝病科和移植外科多学科参与。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Liver transplant(ation) (LT) is the most effective treatment for patients with decompensated liver disease. The increasing prevalence of obesity and type 2 diabetes and the growing number of patients with non-alcoholic fatty liver disease being evaluated for LT, have resulted in a greater proportion of LT candidates presenting with a higher risk of cardiovascular disease. As cardiovascular disease is a major cause of morbidity and mortality after LT, a thorough cardiovascular evaluation pre-LT is crucial. In this review, we discuss the latest evidence on the cardiovascular evaluation of LT candidates and we focus on the most prevalent conditions, namely ischaemic heart disease, atrial fibrillation and other arrhythmias, valvular heart disease, and cardiomyopathies. LT candidates undergo an electrocardiogram, a resting transthoracic echocardiography and an assessment of their cardiopulmonary functional ability as part of their standardised pre-LT work-up. Further diagnostic work-up is undertaken based on the results of the baseline evaluation and may include a coronary computed tomography angiography in patients with cardiovascular risk factors. The evaluation of potential LT candidates for cardiovascular disease requires a multidisciplinary approach, with input from anaesthetists, cardiologists, hepatologists and transplant surgeons.
引用
- Tsochatzis EA, Watt KD, VanWagner LB, et al. Evaluation of recipients with significant comorbidity - Patients with cardiovascular disease. J Hepatol. 2023. PMID: 37208096. doi:10.1016/j.jhep.2023.03.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。